Genzyme Accuses Shire Of Making False Bone Drug Claims

Law360, New York (July 30, 2012, 7:32 PM EDT) -- Sanofi SA subsidiary Genzyme Corp. filed a lawsuit Monday in Massachusetts accusing rival Shire Human Genetic Therapies Inc. of misleading consumers by issuing a press release touting purported clinical evidence that its bone disease drug is superior to Genzyme’s market-leading Cerezyme.

Genzyme is fighting back against a June 28 Shire release that purported to describe new data from a head-to-head clinical trial showing Shire’s VPRIV drug for the treatment of Gaucher-related bone disease improved lumbar spine density while Genzyme’s Cerezyme did not, saying the conclusions come...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.